News

Filter

Current filters:

quizartinib

Daiichi Sankyo to buy Ambit Biosciences for up to $410 million

Daiichi Sankyo to buy Ambit Biosciences for up to $410 million

29-09-2014

Daiichi Sankyo and Ambit Biosciences have entered into a definitive merger agreement under which Daiichi…

Ambit BiosciencesBiotechnologyDaiichi SankyoJapanMergers & AcquisitionsOncologyquizartinib

Astellas ends FLT3 deal with Ambit; reports on flu vaccine ASP7374

12-03-2013

The US subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) and USA-based privately held firm…

Ambit BiosciencesASP7374Astellas PharmaLicensingOncologyPharmaceuticalquizartinibResearchVaccines

Financing for Life Sciences Entrepreneurs antiplatelet candidate NmC; and Ambit's AML drug

06-11-2012

Life Science Entrepreneurs, a Spanish company dedicated to the early-stage development of high-risk/very…

Ambit BiosciencesCardio-vascularFinancialLife Sciences EntrepreneursNmCOncologyPharmaceuticalquizartinibResearch

Acute myeloid leukemia market to be worth $1.67 billion by 2020

20-12-2011

The market for acute myeloid leukemia therapeutics market in the G8 countries (USA, Canada, UK, Germany,…

Ambit BiosciencesMarkets & MarketingOncologyPharmaceuticalquizartinib

COMPANY SPOTLIGHT

Menarini

Back to top